| http://www.w3.org/ns/prov#value | - In the Board's view the documents as originally filed describe AHF-enriched compositions comprising a human Factor VIII concentrate essentially free of blood clotting enzymes (see above points 2.4 to 2.6) and having been treated by heating for a predetermined period of time at a temperature between 60??C and 125??C (see whole content of the disclosure and in particular Table I and Claim 15) which
|
